BLUEBIRD BIO INC's ticker is BLUE and the CUSIP is 09609G100. A total of 281 filers reported holding BLUEBIRD BIO INC in Q2 2020. The put-call ratio across all filers is 1.27 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,383,808 | +68.8% | 455,200 | +82.7% | 1.18% | +91.5% |
| Q2 2023 | $819,868 | +129421.0% | 249,200 | +25.1% | 0.62% | +24.0% |
| Q1 2023 | $633 | -6.6% | 199,200 | +103.3% | 0.50% | +3.5% |
| Q4 2022 | $678 | -99.9% | 98,000 | 0.0% | 0.48% | +9.6% |
| Q3 2022 | $620,000 | +52.7% | 98,000 | 0.0% | 0.44% | +48.1% |
| Q2 2022 | $406,000 | -0.2% | 98,000 | +16.7% | 0.30% | +0.7% |
| Q1 2022 | $407,000 | -51.5% | 84,000 | 0.0% | 0.29% | -45.8% |
| Q4 2021 | $839,000 | -47.7% | 84,000 | 0.0% | 0.54% | -50.5% |
| Q3 2021 | $1,605,000 | -32.2% | 84,000 | +13.5% | 1.09% | -22.9% |
| Q2 2021 | $2,367,000 | +4.0% | 74,000 | -2.0% | 1.42% | +4.8% |
| Q1 2021 | $2,276,000 | -15.2% | 75,500 | +21.8% | 1.35% | -12.6% |
| Q4 2020 | $2,683,000 | -58.6% | 62,000 | -48.3% | 1.55% | -28.5% |
| Q3 2020 | $6,474,000 | +76.8% | 120,000 | +100.0% | 2.16% | -2.3% |
| Q2 2020 | $3,662,000 | – | 60,000 | – | 2.21% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 4,282,827 | $13,019,794 | 1.84% |
| Birchview Capital, LP | 455,200 | $1,383,808 | 1.18% |
| PFM Health Sciences, LP | 6,040,934 | $18,364,439 | 0.86% |
| Lion Point Capital, LP | 531,256 | $1,615,018 | 0.72% |
| Endurant Capital Management LP | 251,785 | $765,426 | 0.69% |
| Bleichroeder LP | 900,000 | $2,736,000 | 0.67% |
| Connacht Asset Management LP | 31,634 | $96,167 | 0.57% |
| Granahan Investment Management | 5,137,778 | $15,618,845 | 0.56% |
| Frazier Life Sciences Management, L.P. | 1,709,907 | $5,198,117 | 0.34% |
| Contrarius Investment Management Ltd | 1,308,002 | $3,976 | 0.22% |